Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

Viatris

Status and phase: Completed; Phase 3

Conditions: Psychotic Disorders; Schizophrenia; Schizoaffective Disorder

Treatments: Drug: ziprasidone versus olanzapine , risperidone or quetiapine; Behavioral: Panss , CGI-C, UKU-SERS-Pa; Procedure: Blood tests

Study type: Interventional

Funder types: Industry

Identifiers

NCT00159770

A1281079

Details and patient eligibility

About

Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV).
• Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator

Exclusion criteria

• A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)